# 2013/2017 H7N9 Prime-Boost Interval

> **NCT03589807** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 180 (actual)

## Conditions studied

- Avian Influenza
- Influenza Immunisation

## Interventions

- **BIOLOGICAL:** A/H7N9
- **DRUG:** AS03
- **BIOLOGICAL:** Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013
- **OTHER:** Phosphate Buffered Saline (PBS) diluent

## Key facts

- **NCT ID:** NCT03589807
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-21
- **Primary completion:** 2020-06-14
- **Final completion:** 2020-06-14
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2021-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03589807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03589807, "2013/2017 H7N9 Prime-Boost Interval". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03589807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*